Trials / Completed
CompletedNCT03804996
Study of TG-1801 in Subjects With B-Cell Lymphoma
A Phase 1 First-in-Human Study of Bispecific Antibody TG-1801 in Subjects With B-Cell Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- TG Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase 1 first in human Study to Assess the Bispecific Antibody TG-1801 in Subjects with B-Cell Lymphoma
Detailed description
This is an open-label, multi-center, accelerated titration design study. Planned enrollment includes 1 subject at low dose levels. Subjects will receive weekly infusions of TG-1801 in a 4 week-cycles.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TG-1801 | Intravenous infusion over 1 hour every 4 weeks |
| BIOLOGICAL | Ublituximab | "recombinant chimeric anti-CD20 monoclonal antibody, available in 25 mg/mL administered as an IV infusion once every 4 weeks" |
Timeline
- Start date
- 2019-03-05
- Primary completion
- 2024-02-21
- Completion
- 2024-02-21
- First posted
- 2019-01-15
- Last updated
- 2024-04-08
Locations
3 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT03804996. Inclusion in this directory is not an endorsement.